IN THE LAB

In the lab

Our team is focused on expanding the applications and continuing the research and development of Nanovega technology. The unique capabilities of Nano-Antibodies bring great hope to cancer research, diagnostics, and eventually therapeutics with a technology that is safer, more effective, and less costly than current antibody-based technologies. We are committed to bringing this exciting tool to the scientists and healthcare professionals who make a difference in our lives.


Support

  • American Human Genetics Society
  • American Protein Society
  • American Antibody Society
  • American Medical Association
  • American Society for Clinical Chemistry
  • Wisconsin Alumni Research Foundation
  • Wisconsin Medical Foundation
  • American Society for Clinical Oncology
Targeted molecule
Antibody
Reporter (detection mode)
BioTag
Price

EGFR
anti-EGFR snAb
fluorescent (619nm)
anti- EGFR-F
Contact us
EGFR
anti-EGFR snAb
para-magnetic (0.4 - 11T)
anti- EGFR-M
Contact us
EGFR
anti-EGFR snAb
x-ray opaque (1.0 - 150keV)
anti- EGFR-X
Contact us
EGFR
anti-EGFR snAb
ultra-sound
anti- EGFR-S
Contact us

EGFRvIII
anti-EGFRvIII snAb
fluorescent (619nm)
anti-EGFRvIII-F
Contact us
EGFRvIII
anti-EGFRvIII snAb
para-magnetic (0.4 - 11T)
anti-EGFRvIII-M
Contact us
EGFRvIII
anti-EGFRvIII snAb
x-ray opaque (1.0 - 150keV)
anti-EGFRvIII-X
Contact us
EGFRvIII
anti-EGFRvIII snAb
ultra-sound
anti-EGFRvIII-S
Contact us

HER2
anti-HER2 snAb
fluorescent (619nm)
anti-HER2-F
Contact us
HER2
anti-HER2 snAb
para-magnetic (0.4 - 11T)
anti-HER2-M
Contact us
HER2
anti-HER2 snAb
x-ray opaque (1.0 - 150keV)
anti-HER2-X
Contact us
HER2
anti-HER2 snAb
ultra-sound
anti-HER2-S
Contact us

CD44
anti-CD44 snAb
fluorescent (619nm)
anti-CD44-F
Contact us
CD44
anti-CD44 snAb
para-magnetic (0.4 - 11T)
anti-CD44-M
Contact us
CD44
anti-CD44 snAb
x-ray opaque (1.0 - 150keV)
anti-CD44-X
Contact us
CD44
anti-CD44 snAb
ultra-sound
anti-CD44-S
Contact us

CD44v6
anti-CD4 v64 snAb
fluorescent (619nm)
anti-CD44v6-F
Contact us
CD44v6
anti-CD4 v64 snAb
para-magnetic (0.4 - 11T)
anti-CD44v6-M
Contact us
CD44v6
anti-CD4 v64 snAb
x-ray opaque (1.0 - 150keV)
anti-CD44v6-X
Contact us
CD44v6
anti-CD4 v64 snAb
ultra-sound
anti-CD44v6-S
Contact us


Title
fluorescent at 619nm
BT HTFR F619
superparamagnetic at 0.4 - 11T
BT HTFR SPM
x-ray opaque at 10 - 150keV
BT HTFR XR
Title
HTFR fluorescent at 619nm
BT HTFR F619
HEGFR fluorescent at 619nm
BT HEGFR1 F619
HEGFR2 fluorescent at 619nm
BT HEGFR1 F619
HEGFRvIII fluorescent
BT HEGFRvIII

Synthetic Nano-Antibodies (snAbs)

Synthetic Nano-Antibodies (snAbs) are biomolecules designed in silico and manufactured in vitro with no involvement of animals. They have the three-dimensional structure corresponding to the variable fragments of antibodies – the targeting domains of all kinds of antibodies.  Initial constructs were patterned based upon modeling of the human IgG molecules synthesized in vitro by human B cells. To date, the snAbs were manufactured against cancers of breast, ovary, testis, prostate, but the works on other cancers continue.


BioTags

The snAbs are incorporated as parts of more complex molecules – BioTags. In there, they serve as the targeting domains guiding BioTags to selected cells. The BioTags are designed in silico and manufactured in vitro. In addition to the targeting domains, they have incorporated other domains allowing them to fulfill other functions:  internalizations into the cells, entering selected cell organelles (e.g., mitochondria to reach mitochondrial DNA or nuclei to reach specific genes); escaping some cellular organelles to avoid destruction (e.g., lysosomes). Therefore, they are de facto non-viral vectors.


Protection of Intellectual Property

All the elements of biomolecular engineering are protected by the patent applications at the USPTO and WIPO. They also cover all aspects of streamlining into the clinics.


External validation of biotechnology

The DNA, mRNA, and AA sequences are accessible through NCBI, USPTO, and WIPO publications. They are free for academic works, but the IP is protected for commercial purposes.


Verification of the results by publications in peer-reviewed journals

All the data from the laboratory studies, as well as the results of the small scale clinical trials were published in the peer-reviewed journals and indexed in PubMed.

Synthetic nanoantibodies in point of care devices (POCs) for precision medicine

The synthetic nanoantibodies, due to their exquisite specificity, excellent sensitivity, small sizes, and dedicated anchoring domains, are uniquely suitable for saturating nano-chips of point of care devices (POCs). The readouts from the chips interfaced with the smart phones are transmitted to the telemedicine centers for analysis. With the rapidly increasing requirements of the FDA for performing pharmacogenomic tests, prior to prescribing and administering medications, the snAbs, as the parts of the POCs, become integral part of the precision medicine.


Highlighting cancer tissue during oncological surgery

The very main problem for surgeons pursuing debulking surgery of a cancerous tumor is to remove its maximal volume, while leaving most of healthy tissues undisturbed. This is very difficult task, as in the operating field it is often very difficult to distinguish cancerous tumor from healthy tissue. The snAbs and BioTags offer a way to solve this problem. As we demonstrated, the fluorescent snAbs label the cancer cells with high efficacy. They highlight only the tumor cells during the surgery. Therefore, they can guide the surgeons in tractu of the operation. As such, the snAbs open the routes for laser-guided and laser-performed surgery.


Isolating spectra of single cancer cells for next generation sequencing of their genomes

The two main problems for systemic chemical therapy of cancer are: therapeutic resistance and adverse effects. The cancers are heterogenous, i.e., hey consist of different populations of cells, which are refractive or responding to therapy. To date, determination of the therapeutic efficacy is practically ex iuvantibus. Whole genome next generation sequencing can resolve this problem if it is conducted not on homogenates of all cells, but on single cells representing specific populations of cells within the tumor. Systemic chemo-therapeutics target the cancer and healthy cells alike. The assumption is that cancer cells are little more sensitive than healthy cells. Nevertheless, pursuing chemotherapy is equivalent to walking a very thin line between killing the cancer and hurting the patient. Targeted therapeutics are aimed to change this paradigm by delivering the therapeutic drug or genes to the cancer cells only,but not to the healthy cells. The snAbs are the primary tool for the avant-garde of physicians and scientists pioneering personalized medicine. With the very high specificity and sensitivity, they facilitate isolating single cells and NGS of their genomes.


Molecular imaging of cancer in vivo

BioTags are engineered on such a way that they specialized domains hosting various reporting atoms. Therefore, they are compatible with all modern imaging equipment and medical infrastructure including but not limited to X-Ray, MRI, CAT and PET.


Protection of Intellectual Property

All the elements of biomolecular engineering are protected by the patent applications at the USPTO and WIPO. They also cover all aspects of streamlining into the clinics.


External validation of biotechnology

The DNA, mRNA, and AA sequences are accessible through NCBI, USPTO, and WIPO publications. They are free for academic works, but the IP is protected for commercial purposes.


Verification of the results by publications in peer-reviewed journals

All the data from the laboratory studies, as well as the results of the small scale clinical trials were published in the peer-reviewed journals and indexed in PubMed.